泰福-KY (6541.TW)

39.55 +2.60 (+7.04%) 收市：01:30PM CST

泰福-KY

802 West Bay Road
Grand Pavilion Hibiscus Way PO Box 31119
George Town KY1-1205
Cayman Islands

https://www.tanvex.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Lin-Cheng Chen J.D.	Chairman & CEO	5k	無	1971
Wen Chung Yeh	Chief Financial Officer	無	無	無
Val Chen	Director of Operation Management & Corporate Governance Officer	無	無	無
Mr. James Williamson	Accounting Officer	無	無	無
Mr. Zheng Xia	Chief Technology Officer	無	無	無
Linda Grillo	Director of Sales & Marketing	無	無	無
Hsun-Chiang Hsieh	Secretary	無	無	無

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

公司管治

截至 無 止，泰福-KY 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。